- Home
- EPAC vs IMCR Comparison
EPAC vs IMCR Comparison
Compare EPAC & IMCR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EPAC
- IMCR
- Stock Information
- Founded
- EPAC 1910
- IMCR 2008
- Country
- EPAC United States
- IMCR United Kingdom
- Employees
- EPAC N/A
- IMCR N/A
- Industry
- EPAC Industrial Machinery/Components
- IMCR Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- EPAC Technology
- IMCR Health Care
- Exchange
- EPAC Nasdaq
- IMCR Nasdaq
- Market Cap
- EPAC 2.3B
- IMCR 1.8B
- IPO Year
- EPAC N/A
- IMCR 2021
- Fundamental
- Price
- EPAC $42.66
- IMCR $35.24
- Analyst Decision
- EPAC Strong Buy
- IMCR Buy
- Analyst Count
- EPAC 2
- IMCR 8
- Target Price
- EPAC $50.50
- IMCR $57.00
- AVG Volume (30 Days)
- EPAC 350.3K
- IMCR 281.5K
- Earning Date
- EPAC 10-14-2025
- IMCR 11-05-2025
- Dividend Yield
- EPAC 0.09%
- IMCR N/A
- EPS Growth
- EPAC 7.49
- IMCR N/A
- EPS
- EPAC 1.63
- IMCR N/A
- Revenue
- EPAC $608,099,000.00
- IMCR $356,145,000.00
- Revenue This Year
- EPAC $6.24
- IMCR $31.83
- Revenue Next Year
- EPAC $5.86
- IMCR $8.50
- P/E Ratio
- EPAC $26.50
- IMCR N/A
- Revenue Growth
- EPAC 2.82
- IMCR 26.78
- 52 Week Low
- EPAC $36.51
- IMCR $23.15
- 52 Week High
- EPAC $51.91
- IMCR $39.33
- Technical
- Relative Strength Index (RSI)
- EPAC 55.09
- IMCR 56.75
- Support Level
- EPAC $40.90
- IMCR $35.33
- Resistance Level
- EPAC $43.37
- IMCR $37.16
- Average True Range (ATR)
- EPAC 0.94
- IMCR 1.36
- MACD
- EPAC -0.09
- IMCR 0.32
- Stochastic Oscillator
- EPAC 57.52
- IMCR 53.39
About EPAC Enerpac Tool Group Corp.
Enerpac Tool Group Corp provides high-precision tools, controlled-force products, and solutions for precise heavy lifting. The company has one reportable segment, the Industrial Tools & Services (IT&S) Segment. The IT&S segment is engaged in the design, manufacture, and distribution of branded hydraulic and mechanical tools and in providing services and tool rental to the refinery/petrochemical; general industrial; industrial maintenance, repair, and operations (MRO); machining & manufacturing; power generation; infrastructure; mining; and other markets. Geographically, the company has operations in Algeria, Australia, Brazil, France, Germany, Kazakhstan, India, Italy, Japan, Norway, Poland, Saudi Arabia, Singapore, South Africa, South Korea, Spain, and the United Arab Emirates.
About IMCR Immunocore Holdings plc
Immunocore Holdings PLC is a commercial-stage biotechnology company. Using its ImmTAX platform, the company is developing a deep pipeline in multiple therapeutic areas, including clinical stage programs in oncology and infectious disease, pre-clinical programs in autoimmune disease, and earlier pre-clinical programs across three therapeutic areas. The company's main product, KIMMTRAK, is used for the treatment of unresectable or metastatic uveal melanoma (mUM). The other drug candidates in its pipeline include Brenetafusp, IMC-P115C, IMC-T119C, IMC-R117C, IMC-S118AI, IMC-U120AI, and others, being developed as a potential treatment for various oncology, infectious, and autoimmune diseases.